Alimera Q1 revenue up 70% to $23M; adjusted EBITDA positive; reaffirms FY guidance

ALIMERA SCIENCES INC

2024-Q1 EPS reported -$0.12 revenue$23,011,000

Net revenue $23.0M (+70% YoY); US $14.6M (+92%), International $8.5M (+42%).
Net loss $6.3M vs $5.0M loss in Q1 2023; adjusted EBITDA positive $1.8M vs ($2.4M) loss.
Global end user demand 4,028 units (+23% YoY). Reaffirms FY2024 revenue of $105M and ≥20% EBITDA margin.
Completed enrollment in Synchronicity Study (YUTIQ for uveitis); first patient randomized in DRCR Retina Network study for radiation retinopathy.
NICE recommends ILUVIEN for phakic DME patients in UK; increased term loan by $5M with SLR Capital.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ALIMERA SCIENCES INC reported first quarter of 2024 results: revenue $23.0 million. Guidance reaffirmed.

Period: first quarter of 2024
Revenue: $23.0 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

such a filing. ‎ 2 --- EX-99.1 (EX-99.1) --- Exhibit 99.1 FOR IMMEDIATE RELEASE Alimera Sciences Reports First Quarter 202 4 Results · Net Revenue up 70 % to $ 23 Million vs. Q1 202 3 · Global End User Demand Up 2 3 % vs. Q1 202 3 · Re iterates I mproved 2024 Net Revenue and Adjusted EBITDA G uidance ATLANTA , May 14 , 202 4 -- Alimera Sciences,

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001267602-24-000029

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.